Artificial intelligence (AI) studies show promise in enhancing accuracy and efficiency in mammographic screening programs worldwide. However, its integration into clinical workflows faces several challenges, including unintended errors, the need for professional training, and ethical concerns. Notably, specific frameworks for AI imaging in breast cancer screening are still lacking. This study aims to identify the challenges associated with implementing AI in breast screening programs and to apply the Consolidated Framework for Implementation Research (CFIR) to discuss a practical governance framework for AI in this context. Three electronic databases (PubMed, Embase, and MEDLINE) were searched using combinations of the keywords "artificial intelligence," "regulation," "governance," "breast cancer," and "screening." Original studies evaluating AI in breast cancer detection or discussing challenges related to AI implementation in this setting were eligible for review. Findings were narratively synthesized and subsequently mapped directly onto the constructs within the CFIR. A total of 1240 results were retrieved, with 20 original studies ultimately included in this systematic review. The majority (n=19) focused on AI-enhanced mammography, while 1 addressed AI-enhanced ultrasound for women with dense breasts. Most studies originated from the United States (n=5) and the United Kingdom (n=4), with publication years ranging from 2019 to 2023. The quality of papers was rated as moderate to high. The key challenges identified were reproducibility, evidentiary standards, technological concerns, trust issues, as well as ethical, legal, societal concerns, and postadoption uncertainty. By aligning these findings with the CFIR constructs, action plans targeting the main challenges were incorporated into the framework, facilitating a structured approach to addressing these issues. This systematic review identifies key challenges in implementing AI in breast cancer screening, emphasizing the need for consistency, robust evidentiary standards, technological advancements, user trust, ethical frameworks, legal safeguards, and societal benefits. These findings can serve as a blueprint for policy makers, clinicians, and AI developers to collaboratively advance AI adoption in breast cancer screening. PROSPERO CRD42024553889; https://tinyurl.com/mu4nwcxt.

This study aims to create a reliable framework for grading esophageal cancer. The framework combines feature extraction, deep learning with attention mechanisms, and radiomics to ensure accuracy, interpretability, and practical use in tumor analysis. This retrospective study used data from 2,560 esophageal cancer patients across multiple clinical centers, collected from 2018 to 2023. The dataset included CT scan images and clinical information, representing a variety of cancer grades and types. Standardized CT imaging protocols were followed, and experienced radiologists manually segmented the tumor regions. Only high-quality data were used in the study. A total of 215 radiomic features were extracted using the SERA platform. The study used two deep learning models-DenseNet121 and EfficientNet-B0-enhanced with attention mechanisms to improve accuracy. A combined classification approach used both radiomic and deep learning features, and machine learning models like Random Forest, XGBoost, and CatBoost were applied. These models were validated with strict training and testing procedures to ensure effective cancer grading. This study analyzed the reliability and performance of radiomic and deep learning features for grading esophageal cancer. Radiomic features were classified into four reliability levels based on their ICC (Intraclass Correlation) values. Most of the features had excellent (ICC > 0.90) or good (0.75 < ICC ≤ 0.90) reliability. Deep learning features extracted from DenseNet121 and EfficientNet-B0 were also categorized, and some of them showed poor reliability. The machine learning models, including XGBoost and CatBoost, were tested for their ability to grade cancer. XGBoost with Recursive Feature Elimination (RFE) gave the best results for radiomic features, with an AUC (Area Under the Curve) of 91.36%. For deep learning features, XGBoost with Principal Component Analysis (PCA) gave the best results using DenseNet121, while CatBoost with RFE performed best with EfficientNet-B0, achieving an AUC of 94.20%. Combining radiomic and deep features led to significant improvements, with XGBoost achieving the highest AUC of 96.70%, accuracy of 96.71%, and sensitivity of 95.44%. The combination of both DenseNet121 and EfficientNet-B0 models in ensemble models achieved the best overall performance, with an AUC of 95.14% and accuracy of 94.88%. This study improves esophageal cancer grading by combining radiomics and deep learning. It enhances diagnostic accuracy, reproducibility, and interpretability, while also helping in personalized treatment planning through better tumor characterization. Not applicable.

Pneumonia is the leading cause of hospitalisation and mortality among children under five, particularly in low-resource settings. Accurate differentiation between viral and bacterial pneumonia is essential for guiding appropriate treatment, yet it remains challenging due to overlapping clinical and radiographic features. Advances in machine learning (ML), particularly deep learning (DL), have shown promise in classifying pneumonia using chest X-ray (CXR) images. This scoping review summarises the evidence on ML techniques for classifying viral and bacterial pneumonia using CXR images in paediatric patients. This scoping review was conducted following the Joanna Briggs Institute methodology and the PRISMA-ScR guidelines. A comprehensive search was performed in PubMed, Embase, and Scopus to identify studies involving children (0-18 years) with pneumonia diagnosed through CXR, using ML models for binary or multiclass classification. Data extraction included ML models, dataset characteristics, and performance metrics. A total of 35 studies, published between 2018 and 2025, were included in this review. Of these, 31 studies used the publicly available Kermany dataset, raising concerns about overfitting and limited generalisability to broader, real-world clinical populations. Most studies (n=33) used convolutional neural networks (CNNs) for pneumonia classification. While many models demonstrated promising performance, significant variability was observed due to differences in methodologies, dataset sizes, and validation strategies, complicating direct comparisons. For binary classification (viral vs bacterial pneumonia), a median accuracy of 92.3% (range: 80.8% to 97.9%) was reported. For multiclass classification (healthy, viral pneumonia, and bacterial pneumonia), the median accuracy was 91.8% (range: 76.8% to 99.7%). Current evidence is constrained by a predominant reliance on a single dataset and variability in methodologies, which limit the generalisability and clinical applicability of findings. To address these limitations, future research should focus on developing diverse and representative datasets while adhering to standardised reporting guidelines. Such efforts are essential to improve the reliability, reproducibility, and translational potential of machine learning models in clinical settings.

High-grade gliomas, particularly glioblastoma (MeSH:Glioblastoma), are among the most aggressive and lethal central nervous system tumors, necessitating advanced diagnostic and prognostic strategies. This systematic review and epistemic meta-analysis explore the integration of Artificial Intelligence (AI) and Radiomics Inter-field (AIRI) to enhance predictive modeling for tumor progression. A comprehensive literature search identified 19 high-quality studies, which were analyzed to evaluate radiomic features and machine learning models in predicting overall survival (OS) and progression-free survival (PFS). Key findings highlight the predictive strength of specific MRI-derived radiomic features such as log-filter and Gabor textures and the superior performance of Support Vector Machines (SVM) and Random Forest (RF) models, achieving high accuracy and AUC scores (e.g., 98% AUC and 98.7% accuracy for OS). This research demonstrates the current state of the AIRI field and shows that current articles report their results with different performance indicators and metrics, making outcomes heterogenous and hard to integrate knowledge. Additionally, it was explored that today some articles use biased methodologies. This study proposes a structured AIRI development roadmap and guidelines, to avoid bias and make results comparable, emphasizing standardized feature extraction and AI model training to improve reproducibility across clinical settings. By advancing precision medicine, AIRI integration has the potential to refine clinical decision-making and enhance patient outcomes.